Afya Limited SEC filings document the company as a foreign private issuer reporting on Form 6-K and presenting financial information in Brazilian reais under IFRS. The filings include unaudited interim and annual consolidated financial statements, operating-result releases and balance-sheet disclosures covering cash, receivables, property and equipment, right-of-use assets, intangible assets, loans and financing, lease liabilities and accounts payable to selling shareholders.
The filing record also documents Afya’s capital-allocation actions, including dividend approvals and share repurchase disclosures, as well as medical-seat authorizations for Brazilian campuses and board-governance changes. These reports connect Afya’s education and medical practice solutions business with formal disclosures on capital structure, liquidity, campus approvals, ownership-related obligations and governance matters.
Afya Ltd filed an initial insider ownership report for director Pereira de Paula Miguel Filisbino. This Form 3 does not report any purchases, sales, gifts, or other transactions, and it shows no derivative positions or other holdings in the sections visible in this data.
Afya Ltd director Vanessa Claro Lopes filed an initial Form 3 reporting her beneficial ownership in the company. The filing shows she directly holds 1,315 Class A common shares following the reported position. This is a registration of existing holdings rather than a new buy or sell transaction.
Afya Ltd filed a Form 3 identifying Dominik Dalkmann Benedikt Karl as a director and reporting person. The insider filing data show no reported share transactions or derivative positions, indicating this is an initial ownership statement rather than a report of buys or sells.
Afya Limited files a Form 144 notice reporting a proposed sale of 150,000 Class A common shares with an aggregate value of $2,064,000.00, listed for sale through Itau International Securities Inc on 03/17/2026 on Nasdaq Global Select.
The filing also lists recent acquisitions that affect available holdings: 17,953 shares from a Restricted Share Units Program (05/01/2023), 38,027 shares from RSUs (05/01/2025), and 100,000 shares issued under a Stock Option Plan (S-8) (06/27/2025), plus an entry showing $2,064,000.00 aggregate and a separate date 06/09/2025 tied to a cash-related line item.
Afya Limited reported strong fourth-quarter and full-year 2025 results, highlighting solid growth, margin expansion and balance-sheet strengthening. Full-year revenue reached R$3,697.3 million, up 11.9% year over year, while Adjusted EBITDA rose 15.4% to R$1,680.3 million, lifting the Adjusted EBITDA margin to 45.4%, an increase of 130 basis points.
Net income grew 18.4% to R$768.4 million and Adjusted Net Income increased 9.9% to R$901.7 million. Basic EPS climbed 18.7% to R$8.32. Afya reduced Net Debt excluding IFRS 16 to R$1,369.5 million and brought Net Debt/Adjusted EBITDA down to 0.8x, supported by R$1,547.6 million in operating cash flow and a 93.7% operating cash conversion ratio.
The board approved a share repurchase program of up to 4,000,000 Class A shares through December 31, 2026 and declared a 2025 cash dividend of R$307.4 million, equal to 40% of consolidated net income. For 2026, Afya guides for revenue between R$3,950 million and R$4,100 million and Adjusted EBITDA between R$1,700 million and R$1,800 million, excluding future acquisitions.
Afya Limited reported that its board approved a cash dividend of R$307.4 million, equal to 40% of consolidated net income for the year ended December 31, 2025. The dividend equals R$3.446838 per share and will be paid in U.S. dollars on April 6, 2026 to shareholders of record as of March 25, 2025, using the PTAX exchange rate published on March 13, 2026. Management stated that, together with its share repurchase program, Afya expects to distribute 50% of 2025 consolidated net income, highlighting a strong focus on shareholder returns.
Afya Limited reported strong unaudited 2025 results, with revenue rising to R$3,697,255 thousand from R$3,304,329 thousand in 2024, driven mainly by its undergraduate medical education business.
Net income increased to R$768,443 thousand in 2025 from R$648,920 thousand in 2024, and basic earnings per share grew to 8.32 from 7.01. Operating income reached R$1,213,110 thousand, while finance expenses remained significant at R$561,024 thousand.
The company generated strong operating cash flow of R$1,531,587 thousand in 2025, ending the year with cash and cash equivalents of R$1,125,381 thousand. Afya expanded its medical seat base through the FUNIC asset acquisition in 2025 and the Unidom business acquisition in 2024, adding new campuses and licenses. In 2025 it also recognized R$109,458 thousand of additional income tax expense related to Brazil’s new OECD Pillar Two minimum tax.
Afya Limited reported that Brazil’s Ministry of Education, through the Secretary of Regulation and Supervision of Higher Education, authorized an increase of 63 medical seats at its Afya Abaetetuba campus (ITPAC), bringing that campus to 113 seats.
Afya Cametá, an approved but non-operating medical school in the same health region, will remain non-operational, which created the capacity for these additional seats at Afya Abaetetuba. Across all campuses, Afya now has 3,766 approved medical seats, reinforcing its focus on expanding high-quality medical education in Brazil.
Afya Limited filed a Form S-8 to register additional Class A common shares for its equity incentive plans. The filing covers 3,393,220 shares authorized for issuance under the Amended and Restated Stock Option Plan and 987,016 shares authorized for issuance under the Restricted Stock Plan.
The registration incorporates by reference Afya’s Annual Report on Form 20-F for the year ended December 31, 2024 and subsequent Exchange Act reports. The shares have a par value of $0.00005 per share. This administrative filing expands the pool of shares available for future grants under the company’s employee equity plans.